Literature DB >> 29563616

Type I interferons promote the survival and proinflammatory properties of transitional B cells in systemic lupus erythematosus patients.

Mei Liu1, Qiang Guo2, Chunmei Wu2, Delphine Sterlin1, Shyamal Goswami1, Ying Zhang1, Teng Li1, Chunde Bao2, Nan Shen2, Qiong Fu3, Xiaoming Zhang4.   

Abstract

A hallmark of systemic lupus erythematosus (SLE) is the breaking of B-cell tolerance with the generation of high-affinity autoantibodies; however, the antibody-independent features of the B-cell compartment in SLE are less understood. In this study, we performed an extensive examination of B-cell subsets and their proinflammatory properties in a Chinese cohort of new-onset SLE patients. We observed that SLE patients exhibited an increased frequency of transitional B cells compared with healthy donors and rheumatoid arthritis patients. Plasma from SLE patients potently promoted the survival of transitional B cells in a type I IFN-dependent manner, which can be recapitulated by direct IFN-α treatment. Furthermore, the effect of IFN-α on enhanced survival of transitional B cells was associated with NF-κB pathway activation and reduced expression of the pro-apoptotic molecule Bax. Transitional B cells from SLE patients harbored a higher capacity to produce proinflammatory cytokine IL-6, which was also linked to the overactivated type I IFN pathway. In addition, the frequency of IL-6-producing transitional B cells was positively correlated with disease activity in SLE patients, and these cells were significantly reduced after short-term standard therapies. Thus, the current study provides a direct link between type I IFN pathway overactivation and the abnormally high frequency and proinflammatory properties of transitional B cells in active SLE patients, which contributes to the understanding of the roles of type I IFNs and B cells in the pathogenesis of SLE.

Entities:  

Keywords:  Systemic lupus erythematosus; apoptosis; interleukin 6; transitional B cells; type I interferons

Mesh:

Substances:

Year:  2018        PMID: 29563616      PMCID: PMC6461980          DOI: 10.1038/s41423-018-0010-6

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  1 in total

1.  Systemic lupus erythematosus disease activity index 2000.

Authors:  Dafna D Gladman; Dominique Ibañez; Murray B Urowitz
Journal:  J Rheumatol       Date:  2002-02       Impact factor: 4.666

  1 in total
  15 in total

1.  Transitional B cells in quiescent SLE: An early checkpoint imprinted by IFN.

Authors:  Yannick Dieudonné; Vincent Gies; Aurélien Guffroy; Céline Keime; Anna K Bird; Jane Liesveld; Jennifer L Barnas; Vincent Poindron; Nawal Douiri; Pauline Soulas-Sprauel; Thierry Martin; Eric Meffre; Jennifer H Anolik; Anne-Sophie Korganow
Journal:  J Autoimmun       Date:  2019-05-10       Impact factor: 7.094

Review 2.  The Plasticity of Newly Formed B Cells.

Authors:  Natalia V Giltiay; Daniela Giordano; Edward A Clark
Journal:  J Immunol       Date:  2019-12-15       Impact factor: 5.422

Review 3.  The pathogenic role of innate lymphoid cells in autoimmune-related and inflammatory skin diseases.

Authors:  Suqing Zhou; Qianwen Li; Haijing Wu; Qianjin Lu
Journal:  Cell Mol Immunol       Date:  2020-03-19       Impact factor: 11.530

Review 4.  Cutaneous and systemic connections in lupus.

Authors:  Mitra P Maz; J Michelle Kahlenberg
Journal:  Curr Opin Rheumatol       Date:  2020-11       Impact factor: 4.941

5.  High TLR7 Expression Drives the Expansion of CD19+CD24hiCD38hi Transitional B Cells and Autoantibody Production in SLE Patients.

Authors:  Ting Wang; John Marken; Janice Chen; Van Bao Tran; Quan-Zhen Li; Mengtao Li; Karen Cerosaletti; Keith B Elkon; Xiaofeng Zeng; Natalia V Giltiay
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 7.561

6.  Lupus-associated atypical memory B cells are mTORC1-hyperactivated and functionally dysregulated.

Authors:  Chunmei Wu; Qiong Fu; Qiang Guo; Sheng Chen; Shyamal Goswami; Shuhui Sun; Teng Li; Xingjian Cao; Fuying Chu; Zechuan Chen; Mei Liu; Yuanhua Liu; Ting Fu; Pei Hao; Yi Hao; Nan Shen; Chunde Bao; Xiaoming Zhang
Journal:  Ann Rheum Dis       Date:  2019-05-29       Impact factor: 19.103

Review 7.  Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus.

Authors:  I-Tsu Chyuan; Hong-Tai Tzeng; Ji-Yih Chen
Journal:  Cells       Date:  2019-08-23       Impact factor: 6.600

Review 8.  Interferons in Systemic Lupus Erythematosus.

Authors:  Sirisha Sirobhushanam; Stephanie Lazar; J Michelle Kahlenberg
Journal:  Rheum Dis Clin North Am       Date:  2021-06-10       Impact factor: 2.032

Review 9.  Transitional B cells involved in autoimmunity and their impact on neuroimmunological diseases.

Authors:  Yang Zhou; Ying Zhang; Jinming Han; Mengge Yang; Jie Zhu; Tao Jin
Journal:  J Transl Med       Date:  2020-03-17       Impact factor: 5.531

Review 10.  Peripheral B Cell Subsets in Autoimmune Diseases: Clinical Implications and Effects of B Cell-Targeted Therapies.

Authors:  Wanlin Jin; Zhaohui Luo; Huan Yang
Journal:  J Immunol Res       Date:  2020-03-23       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.